Research Analysts Release Outlook for Omega Therapeutics Inc Earnings in Q1 2023 (NASDAQ: OMGA)
Omega Therapeutics Inc (NASDAQ: OMGA) – Piper Sandler stock research analysts released their estimates for first quarter 2023 earnings per share for Omega Therapeutics shares in a report released on Wednesday, November 10. Piper Sandler analyst E. Tenthoff expects the company to post earnings of ($ 0.80) per share for the quarter. Piper Sandler currently has an “overweight” rating and a price target of $ 30.00 on the stock. Piper Sandler also released second quarter 2023 earnings estimates for Omega Therapeutics at ($ 0.86) per share, third quarter 2023 earnings at ($ 0.93) per share, and fiscal 2023 earnings. at ($ 3.59) per share. Omega Therapeutics (NASDAQ: OMGA) last released its quarterly results on Wednesday, November 10. The company reported ($ 0.57) EPS for the quarter, missing ($ 0.09) Zacks’ consensus estimate ($ 0.48).
Other equity research analysts have also recently published reports on the company. The Goldman Sachs group launched coverage on Omega Therapeutics in a report on Tuesday, August 24. They issued a “neutral” rating and a target price of $ 22.00 for the company. Wedbush began covering Omega Therapeutics in a research report on Tuesday, August 24. They set an “outperformance” rating and a target price of $ 36.00 for the stock. Zacks investment research downgraded Omega Therapeutics from a âholdâ rating to a âbuyâ rating and set a target price of $ 23.00 on the stock in a research report released Thursday. Finally, Jefferies Financial Group began covering Omega Therapeutics in a research report on Tuesday, August 24. They set a âbuyâ rating and a target price of $ 30.00 on the stock. One analyst rated the stock with a conservation rating and four gave the company a buy rating. According to MarketBeat.com, the company currently has an average âBuyâ rating and an average target price of $ 28.20.
The fierce copper game is close to production.
OMGA shares opened at $ 22.02 on Thursday. The company has a 50-day simple moving average of $ 21.28. Omega Therapeutics has a fifty-two week low of $ 15.50 and a fifty-two week high of $ 31.41.
A number of hedge funds and other institutional investors have recently changed their positions in OMGA. BlackRock Inc. purchased a new position in Omega Therapeutics shares in the third quarter valued at approximately $ 18,061,000. Platinum Investment Management Ltd. purchased a new position in Omega Therapeutics during the third quarter for a value of approximately $ 9,425,000. Monashee Investment Management LLC purchased a new equity stake in Omega Therapeutics in the 3rd quarter valued at $ 8,316,000. The Michigan State Pension System purchased a new stake in Omega Therapeutics shares in the third quarter for a value of $ 5,544,000. Finally, Victory Capital Management Inc. purchased a new position in Omega Therapeutics shares in the third quarter for a value of $ 2,301,000. Institutional investors and hedge funds hold 54.25% of the company’s shares.
Omega Therapeutics Company Profile
Omega Therapeutics Inc is a developing biotechnology company. Its OMEGA Epigenomic Programming (TM) platform harnesses the power of epigenetics to develop a new class of programmable epigenetic drugs targeting DNA sequence and encoded by mRNA. Omega Therapeutics Inc is based in CAMBRIDGE, Mass.
Recommended Story: Risk Tolerance And Your Investment Decisions
This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [emailÂ protected]
Should you invest $ 1,000 in Omega Therapeutics now?
Before you consider Omega Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and Omega Therapeutics was not on the list.
Although Omega Therapeutics currently has a âBuyâ rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here